Open AccessClinical experience of using 0.1% mometasone furoate cream for external treatment of steroid-responsive dermatoses
Author(s) -
А. В. Стаценко,
А. В. Стаценко,
И. Э. Белоусова,
И. Э. Белоусова,
В. Р. Хайрутдинов,
В. Р. Хайрутдинов,
М. А. Парфенова,
М. А. Парфенова
Publication year - 2013
Publication title -
vestnik dermatologii i venerologii
Language(s) - English
Resource type - Journals
eISSN - 2313-6294
pISSN - 0042-4609
DOI - 10.25208/vdv622
Subject(s) - mometasone furoate , tolerability , medicine , atopic dermatitis , dermatology , psoriasis , adverse effect , scorad , visual analogue scale , clinical efficacy , itching , drug , allergic dermatitis , pharmacology , surgery , corticosteroid , dermatology life quality index
An up-to-date synthetic non-fluorated topical glucocorticosteroid, Histan-N (0.1% mometasone furoate cream), has an evident antiinflammatory, anti-allergic, immune-suppressive and antiproliferative action. Goal. To assess the efficacy, safety and tolerability of Histan-N for the treatment of patients with steroid-responsive dermatoses. Materials and methods. As many as 80 patients with eczema, psoriasis, atopic dermatitis, dermatitis and allergic dermatitis as well as lichen acuminatus underwent treatment. All of the patients received general pathogenetic therapy and external treatment with Histan-N. The treatment efficacy was assessed based on the trends of such dermatological indices as PASI, SCORAD and EASI as well as visual analog scale. Results. Dermatological indices reduced by 70%—90% as compared to the baseline against the background of treatment. Conclusion. The clinical results obtained for Histan-N demonstrate a substantial clinical effect of the drug, absence of adverse effects and high safety of the drug.